Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187254 | 0.95 | THRB (0.51) | THRBL3MBTL1ATMEPHX1KMT2A | |
| SCHEMBL655026 | 0.92 | HSD11B1 (0.62) | THRBL3MBTL1ATMEPHX1KMT2A | |
| SCHEMBL655025 | 0.92 | HSD11B1 (0.62) | THRBL3MBTL1ATMEPHX1KMT2A | |
| SCHEMBL13779840 | 0.88 | EPHX1 (0.50) | THRBL3MBTL1ATMEPHX1KMT2A | |
| SCHEMBL18926997 | 0.88 | EPHX1 (0.70) | L3MBTL1EPHX1ALDH1A1CYP2C9HSD11B1 | |
| SCHEMBL2695461 | 0.87 | GAA (0.55) | THRBL3MBTL1ATMEPHX1KMT2A | |
| SCHEMBL28521207 | 0.86 | EPHX1 (0.60) | L3MBTL1EPHX1ALDH1A1CYP2C9HSD11B1 | |
| SCHEMBL29150085 | 0.86 | THRB (0.54) | THRBL3MBTL1ATMEPHX1KMT2A | |
| SCHEMBL16152211 | 0.84 | L3MBTL1 (0.62) | THRBL3MBTL1ATMKMT2AMEN1 | |
| SCHEMBL2980638 | 0.84 | EPHX1 (0.55) | THRBL3MBTL1ATMEPHX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113607831-B | Detection method of 4-Boc-aminopiperidine related substance | 河北国龙制药有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-113607831-A | Detection method of 4-Boc-aminopiperidine related substance | 河北国龙制药有限公司 | 2021-11-05 | — | — | CN | claimed |
| CN-113607831-B | Detection method of 4-Boc-aminopiperidine related substance | 河北国龙制药有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-113607831-A | Detection method of 4-Boc-aminopiperidine related substance | 河北国龙制药有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1497269-B1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7320977-B2 | Fibrotic disorders; disorders characterized by harmful buildup of collagen and/or by excessive lysyl oxidase enzymatic activity | BAYER HEALTHCARE AG (DE) | 2008-01-22 | — | — | US | disclosed |
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-05 | — | — | US | disclosed |
| EP-1497269-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | Bayer HealthCare AG (DE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003097612-A1 | SUBSTITUTED 2-PHENYL-3(2H)-PYRIDAZINONES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004015-A1 | Substituted 2-phenyl-3(2h)-pyridazinones | PIR, TPMT, PNPO | THRB 2289/4885L3MBTL1 2051/4885ATM 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.